Publications

Philip Bejon

ONT sequencing identifies a high prevalence of crt sensitive, triple mutant dhfr and single mutant dhps parasites within an ANC population in Nigeria.Adegbola, A. J. Ndwiga, L. Wamae, K. Osoti, V. Bolaji, O. O. Bejon, P. Ochola-Oyier, L. I.
Front Genet, (2024). 15:1470156

Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults.Kinyua, A. W. Turner, L. Kimingi, H. W. Mwai, K. Mwikali, K. Andisi, C. Sim, B. K. L. Bejon, P. Kapulu, M. C. Kinyanjui, S. M. Lavstsen, T. Abdi, A. I. Chmi-Sika Study Team
J Infect, (2024). 89:106252

The mRNA content of plasma extracellular vesicles provides a window into molecular processes in the brain during cerebral malaria.Kioko, M. Mwangi, S. Pance, A. Ochola-Oyier, L. I. Kariuki, S. Newton, C. Bejon, P. Rayner, J. C. Abdi, A. I.
Sci Adv, (2024). 10:eadl2256

A retrospective analysis of P. falciparum drug resistance markers detects an early (2016/17) high prevalence of the k13 C469Y mutation in asymptomatic infections in Northern Uganda.Ogwang, R. Osoti, V. Wamae, K. Ndwiga, L. Muteru, K. Ningwa, A. Tuju, J. Kinyanjui, S. Osier, F. Marsh, K. Bejon, P. Idro, R. Ochola-Oyier, L. I.
Antimicrob Agents Chemother, (2024). 68:e0157623

Tungiasis among children in Kenya is associated with poor nutrition status, absenteeism, poor school performance and high impact on quality of life.Elson, L. Kamau, C. Koech, S. Muthama, C. Gachomba, G. Sinoti, E. Chondo, E. Mburu, E. Wakio, M. Lore, J. Maia, M. Adetifa, I. Orindi, B. Bejon, P. Fillinger, U.
PLoS Negl Trop Dis, (2024). 18:e0011800

Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang, R. Murugu, L. Nkumama, I. N. Nyamako, L. Kai, O. Mwai, K. Murungi, L. Idro, R. Bejon, P. Tuju, J. Kinyanjui, S. M. Osier, F. H. A.
Front Immunol, (2024). 15:1360220

Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Asante, K. P. Mathanga, D. P. Milligan, P. Akech, S. Oduro, A. Mwapasa, V. Moore, K. A. Kwambai, T. K. Hamel, M. J. Gyan, T. Westercamp, N. Kapito-Tembo, A. Njuguna, P. Ansong, D. Kariuki, S. Mvalo, T. Snell, P. Schellenberg, D. Welega, P. Otieno, L. Chimala, A. Afari, E. A. Bejon, P. Maleta, K. Agbenyega, T. Snow, R. W. Zulu, M. Chinkhumba, J. Samuels, A. M. Malaria Vaccine Programme Evaluation, Partners
Lancet, (2024). 403:1660-1670

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu, M. C. Muthumbi, E. Otieno, E. Rossi, O. Ferruzzi, P. Necchi, F. Acquaviva, A. Martin, L. B. Orindi, B. Mwai, K. Kibet, H. Mwanzu, A. Bigogo, G. M. Verani, J. R. Mbae, C. Nyundo, C. Agoti, C. N. Nakakana, U. N. Conti, V. Bejon, P. Kariuki, S. Scott, J. A. G. Micoli, F. Podda, A.
Front Immunol, (2024). 15:1340425

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu, M. Manda-Taylor, L. Balasingam, S. Means, G. Ayiro Malungu, M. Bejon, P. Chi, P. C. Chiu, C. Church, E. C. Correa-Oliveira, R. Day, N. Durbin, A. Egesa, M. Emerson, C. Jambo, K. Mathur, R. Metzger, W. Mumba, N. Nazziwa, W. Olotu, A. Rodgers, J. Sinyiza, F. Talaat, K. Kamerling, I. Weller, C. Baay, M. Neels, P.
Biologicals, (2024). 85:101747

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo, M. S. Dicko, A. Tinto, H. Ouedraogo, J. B. Hamaluba, M. Olotu, A. Beaumont, E. Ramos Lopez, F. Natama, H. M. Weston, S. Chemba, M. Compaore, Y. D. Issiaka, D. Salou, D. Some, A. M. Omenda, S. Lawrie, A. Bejon, P. Rao, H. Chandramohan, D. Roberts, R. Bharati, S. Stockdale, L. Gairola, S. Greenwood, B. M. Ewer, K. J. Bradley, J. Kulkarni, P. S. Shaligram, U. Hill, A. V. S. R. 1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.Kimenyi, K. M. Akinyi, M. Y. Mwikali, K. Gilmore, T. Mwangi, S. Omer, E. Gichuki, B. Wambua, J. Njunge, J. Obiero, G. Bejon, P. Langhorne, J. Abdi, A. Ochola-Oyier, L. I.
BMC Infect Dis, (2024). 24:140

Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.Kibwana, E. Kapulu, M. Bejon, P.
Curr Top Microbiol Immunol, (2024). 445:337-365

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho, J. Sein, Y. Sayed, S. Shah, R. Mwai, K. Saleh, M. Wanjiku, P. Mwacharo, J. Nyagwange, J. Karanja, H. Kutima, B. Gitonga, J. N. Mugo, D. Karanu, A. Moranga, L. Oluoch, V. Shah, J. Mutiso, J. Mburu, A. Nneka, Z. Betti, P. Usyu Mutinda, W. Issak Abdi, A. Bejon, P. Isabella Ochola-Oyier, L. M. Warimwe G Nduati, E. W. M. Ndungu F
Wellcome Open Res, (2023). 8:350

Utility of MALDI-TOF MS for determination of species identity and blood meal sources of primary malaria vectors on the Kenyan coast.Karisa, J. Ominde, K. Tuwei, M. Bartilol, B. Ondieki, Z. Musani, H. Wanjiku, C. Mwikali, K. Babu, L. Rono, M. Eminov, M. Mbogo, C. Bejon, P. Mwangangi, J. Laroche, M. Maia, M.
Wellcome Open Res, (2023). 8:151

Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang, S. Datoo, M. S. Otieno, E. Muiruri, C. Bellamy, D. Gathuri, E. Ngoto, O. Musembi, J. Provstgaard-Morys, S. Stockdale, L. Aboagye, J. Woods, D. Lawrie, A. Roberts, R. Keter, K. Kimani, D. Ndungu, F. Kapulu, M. Njau, I. Orindi, B. Ewer, K. J. Hill, A. V. S. Bejon, P. Hamaluba, M.
Wellcome Open Res, (2023). 8:450

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba, M. Sang, S. Orindi, B. Njau, I. Karanja, H. Kamau, N. Gitonga, J. N. Mugo, D. Wright, D. Nyagwange, J. Kutima, B. Omuoyo, D. Mwatasa, M. Ngetsa, C. Agoti, C. Cheruiyot, S. Nyaguara, A. Munene, M. Mturi, N. Oloo, E. Ochola-Oyier, L. Mumba, N. Mauncho, C. Namayi, R. Davies, A. Tsofa, B. Nduati, E. W. Aliyan, N. Kasera, K. Etyang, A. Boyd, A. Hill, A. Gilbert, S. Douglas, A. Pollard, A. Bejon, P. Lambe, T. Warimwe, G. C. O. V. Vaccine Trial Group
Wellcome Open Res, (2023). 8:182

Low frequency of Plasmodium falciparum hrp2/3 deletions from symptomatic infections at a primary healthcare facility in Kilifi, Kenya.Okanda, D. Ndwiga, L. Osoti, V. Achieng, N. Wambua, J. Ngetsa, C. Lubell-Doughtie, P. Shankar, A. Bejon, P. Ochola-Oyier, L. I.
Front Epidemiol, (2023). 3:1083114

Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study.Otiende, M. Nyaguara, A. Bottomley, C. Walumbe, D. Mochamah, G. Amadi, D. Nyundo, C. Kagucia, E. W. Etyang, A. O. Adetifa, I. M. O. Brand, S. P. C. Maitha, E. Chondo, E. Nzomo, E. Aman, R. Mwangangi, M. Amoth, P. Kasera, K. Ng'ang'a, W. Barasa, E. Tsofa, B. Mwangangi, J. Bejon, P. Agweyu, A. Williams, T. N. Scott, J. A. G.
Nat Commun, (2023). 14:6879

Extracellular vesicles could be a putative posttranscriptional regulatory mechanism that shapes intracellular RNA levels in Plasmodium falciparum.Kioko, M. Pance, A. Mwangi, S. Goulding, D. Kemp, A. Rono, M. Ochola-Oyier, L. I. Bull, P. C. Bejon, P. Rayner, J. C. Abdi, A. I.
Nat Commun, (2023). 14:6447

Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study.Gallagher, K. E. Nyiro, J. Agoti, C. N. Maitha, E. Nyagwange, J. Karani, A. Bottomley, C. Murunga, N. Githinji, G. Mutunga, M. Ochola-Oyier, L. I. Kombe, I. Nyaguara, A. Kagucia, E. W. Warimwe, G. Agweyu, A. Tsofa, B. Bejon, P. Scott, J. A. G. Nokes, D. J.
Influenza Other Respir Viruses, (2023). 17:e13185